News | Radiation Therapy | April 06, 2017

Further Reductions in Radiotherapy to Young Children with Brain Tumors Results in Less Successful Outcomes

Qualitative assessment of Head Start III trial finds more than 30 percent of patients experienced deviations from radiotherapy protocols, which lowered overall survival rates

radiotherapy, radiation therapy, CHLA, Children's Hospital Los Angeles study, young children, brain tumors, outcomes, Pediatric Blood & Cancer

Image courtesy of CHLA.

April 6, 2017 — A team of investigators has determined that young children participating in a clinical trial to assess the effectiveness of reduced radiotherapy did worse when there were deviations from the treatment protocol. Results of the study were available online in advance of publication by Pediatric Blood & Cancer on April 4.

“This study shows that attention to the timing, dose and location of radiation therapy is crucial,” said Kenneth K. Wong, M.D., a radiation oncologist at Children’s Hospital Los Angeles and first author on the study.

This paper is a qualitative assessment of the Head Start III trial, which avoids or delays radiation therapy in children with brain tumors. The Head Start studies represent an innovative approach to the treatment of malignant brain tumors — using high-dose chemotherapy followed by transfusion of blood stem cells — as a substitute for radiation in younger children, where the late side effects of radiation to the developing brain can be particularly detrimental. If disease persists after this course of treatment or if the child is older, they receive radiation therapy. 

In Head Start III, only 31 of 220 children received radiation on study, since the goal of these studies is to reduce radiation exposure. However, of the children who were to receive radiation, a subset (8 of 25) had deviations from the treatment plan. These protocol violations all occurred in children 6 years of age or younger.

“Parents or providers may want to delay the start of radiation or reduce the dose or area of exposure — particularly in very young children,” said Wong. “But in a study already limiting radiation exposure, patients with these kinds of protocol violations experienced worse outcomes.”

For all patients eligible for radiation therapy, those that received treatment according to protocol and began radiation therapy within 11 weeks of recovery from stem cell transfusion had improved overall survival.

To further improve patient outcomes, Wong suggested focusing on reducing protocol violations by reviewing treatment plans prior to initiating radiation therapy. He is currently pursuing funding to continue this work.

Additional contributors to this study include: Girish Dhall and Arthur Olch, Children’s Hospital Los Angeles; Sean All, University of Central Florida College of Medicine; Jonathan Waxer, Tulane University School of Medicine; Rajkumar Venkatramani, Texas Children’s Hospital; Tom Belle Davidson, UCLA; Wafik Zaky, MD Anderson Cancer Center; and Jonathan Finlay, Nationwide Children’s Hospital.

For more information: www.onlinelibrary.wiley.com

Related Content

Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...